OABI vs TWST
OABI: OmniAb is an antibody discovery technology leader that provides pharmaceutical partners with proprietary transgenic animal platforms, AI-driven screening, and bioinformatics tools to accelerate the creation of therapeutic biologics. TWST: Twist Bioscience leverages a proprietary silicon-based platform to mass-produce high-quality synthetic DNA for applications in therapeutics, diagnostics, and research.
Side-by-side fundamentals
| Metric | OABI | TWST | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $4.92 | $149.13 | |
| Market cap | $715M | $9.4B | |
| Net margin FY2025, SEC XBRL | -347.0% | n/a | |
| Operating margin FY2025, SEC XBRL | -369.5% | n/a | |
| ROE FY2025, SEC XBRL | -24.3% | -16.4% | TWST higher |
| ROA FY2025, SEC XBRL | -21.5% | -12.1% | TWST higher |
| Revenue growth (YoY) FY2025, SEC XBRL | -29.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -31.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | OABI higher |
| Beta as of 2026-09-02 | 1.01 | 2.03 | |
| 1-year return as of 2026-10-21 close | +196.1% | +346.6% | TWST higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.